Bromhexine
Expectorants
Drugs, Chinese Herbal
Medicine, Chinese Traditional
Poria
Plants, Medicinal
In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism. (1/19)
Neutrophils are major culprits for the protease/antiprotease imbalance during various lung diseases, that is, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary fibrosis and adult respiratory distress syndrome. Thus, these cells are presently considered an ideal target for the pharmacologic control of tissue injury during these diseases. This study was planned in order to investigate if ambroxol and its precursor bromhexine are actually capable of preventing alpha-1-antitrypsin (A1AT) inactivation by stimulated neutrophils and possibly to look into the mechanisms underlying this event. Ambroxol inhibited the production of superoxide anion by activated neutrophils, whereas bromhexine had no inhibitory effect. Ambroxol decreased the production of hypochlorous acid (HOCl) from activated neutrophils with high efficiency, whereas bromhexine had a modest activity. Ambroxol and bromhexine were capable of limiting the chlorination of monochlorodimedon by HOCl, displaying the capacity of directly scavenging the oxidant. Ambroxol decreased the release of elastase and myeloperoxidase from activated neutrophils, whereas bromhexine was ineffective. Ambroxol prevented the A1AT inactivation by neutrophils, whereas bromhexine was completely ineffective. Among drugs currently available for in vivo use in humans, ambroxol is unique by virtue of its ability to prevent neutrophil-mediated A1AT inactivation via inhibition of HOCl production as well as HOCl scavenging. Also taking into account its capacity for curbing elastase release, the drug displays the potential to lessen the burden of oxidants/proteases and to increase the antiprotease shield at the site of inflammation. Thus, ambroxol appears to be a good candidate for raising attempts to develop new therapeutic histoprotective approaches to inflammatory bronchopulmonary diseases. (+info)Mediastinal pancreatic pseudocyst caused by obstruction of the pancreatic duct was eliminated by bromhexine hydrochloride. (2/19)
A 49-year-old man, who had a 30-year history of drinking the equivalent of 80 g of ethanol per day, underwent a detailed medical examination for cough and dyspnea. Chest-abdominal computed tomography and endoscopic retrograde pancreatography led to the diagnosis of a mediastinal pancreatic pseudocyst resulting from obstruction of the pancreatic duct by a protein plug. The pseudocyst rapidly improved with conservative treatment with camostat mesilate, H2-receptor antagonist and digestive enzymes. Although the patient abstained from alcohol for approximately 6 months, he resumed drinking, leading to recurrent attacks of pancreatitis. Bromhexine hydrochloride was then administered for 6 months, with the expectation that it would have a mucolytic effect on the pancreatic juice, resulting in improvement in the clinical symptoms, pancreatic enzymes and pancreatic exocrine function, as well as elimination of the protein plug. Bromhexine hydrochloride may be a new therapy for pathological states, such as alcoholic chronic pancreatitis, in which there is increased viscosity of the pancreatic juice because of elevated protein concentration, leading to protein plug formation and temporary blockage of the pancreatic duct. (+info)Synchronous germinomas in the pineal and suprasellar region. (3/19)
Synchronous primary intracranial germ cell tumors are rare. Only 5-10% of all germ cell tumors are found as synchronous lesion in pineal and suprasellar region. They are also known by the entity "double mid-line atypical teratoma". An 11-year-old male child presented with polyuria, polydipsia and features of raised intracranial tension. CT scan head revealed well-defined homogenously enhancing lesions in the pineal and suprasellar region. Histopathology examination showed the lesion to be of germ cell origin. (+info)Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study. (4/19)
BACKGROUND: A randomized double-blind placebo controlled clinical study was undertaken to investigate the safety and efficacy of a plant-based formulation (DCBT1234-Lung KR), which earlier through 2 trials was found to improve FEV1 and the quality of life of COPD patients. OBJECTIVE: The efficacy of DCBT1234-Lung KR was assessed using pulmonary function tests, arterial blood gas (ABG) analyses and the clinical symptoms of COPD in a 6-month study period against a matching placebo and a biomedical drug combination (salbutamol+theophylline+bromhexine). METHODS: One hundred and five subjects aged between 35 and 85 years with a smoking history of more than 20 pack years, showing little or no improvement in FEV1 upon a bronchial challenge of 200 microg of inhaled salbutamol and exhibiting ABG percentage of less than 85% of oxygen saturation were taken up for the study. The study had 3 arms viz., the plant-based formulation (DCBT1234-Lung KR), placebo and salbutamol (12 mg/day) plus theophylline (300 mg/day) plus bromhexine (24 mg/day). The end point of the study was determined as an improvement of FEV1 by 200 mL and/or increased ABG values (>90% PaO2) and clinical symptoms like dyspnoea, wheezing, cough, expectoration, disability, and sleep disturbances. RESULTS: DCBT1234-Lung KR patients showed statistically significant (95% level) improvement in FEV1 and PaO2 in comparison with salbutamol+theophylline+bromhexine and placebo patients. Twenty-three per cent of DCBT1234-Lung KR patients, 19% of salbutamol+theophylline+bromhexine group and 12% of placebo group patients showed the desired 200 mL improvement in FEV1 values in comparison with the other 2 arms. Improved PaO2 was observed in 15.4% of the DCBT1234-Lung KR patients while no improvement was seen with patients in any other arms. Symptoms like dyspnoea, wheezing, cough, expectoration, disability and sleep disturbances also significantly reduced in DCBT1234-Lung KR and the biomedical group patients, but not in the placebo arm. CONCLUSIONS: DCBT1234-Lung KR was equivalent, if not better than the present day treatment with salbutamol, theophylline and bromhexine combination in COPD patients and this was ascertained using FEV1 and ABG values. (+info)A case of a GH-producing pituitary adenoma associated with a unilateral headache with autonomic signs. (5/19)
A 66-year-old man suffered from a drug-resistant, left-sided headache with autonomic signs, triggered by the supine position. The acromegalic facies initially suggested a possible increase in basal plasma levels of GH, but routine haematological controls excluded abnormal values of GH. Cerebral and facial CT scan and MRI did not detect any alterations in the nasal sinuses, except for a mucous cyst. Surgical ablation of the cyst did not alleviate the pain. Further endocrinological the pain. Further endocrinological tests demonstrated an increase of IGF-1 (somatomedin C), and another MRI scan of the sellar region confirmed the presence of a pituitary macroadenoma on the left paramedian side. After an initial improvement of the symptomatology due to trans-sphenoidal ablation of a benign GH-producing macroadenoma, the headache worsened again. Pain was well correlated with the increased plasma levels of IGF-1. The patient died suddenly for myocardial infarct. (+info)Pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers. (6/19)
OBJECTIVE: To determine the pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers. METHODS: Twelve subjects received a cefaclor (CEF) treatment, a bromhexine (BHX) treatment, and a co-treatment of CEF and BHX with a 3 x 3 Latin square design. The wash-out time between periods was 14 days. The plasma and urine drug concentrations of CEF and BHX were detected by HPLC-UV and LC/MS, respectively. RESULTS: All the 12 volunteers completed the study. There were no significant differences in AUC 0-t and Cmax of CEF in logarithm between the single administration group of CEF and the co-administration group of CEF with BHX. Two one sided t-test showed that CEF was bioequivalent in the 2 groups. There were no significant differences in tmax, MRT, t1/2, and Clr between the 2 groups. Vd/F was significantly lower in the single CEF group than in the co-administration group of CEF and BHX. There were no significant differences of AUC 0-t and Cmax of BHX in logarithm between the single administration group of BHX and the co-administration group of BHX with CEF. Two one sided t-test showed that BHX was bioequivalent in the 2 groups. There were no significant differences in tmax, MRT, t1/2, Vd/F, and Clr between the 2 groups. CONCLUSION: There is no significant pharmacokinetic parameter change in the drug absorption, metabolism, and excretion, but Vd/F of CEF significant increases in the co-administration of CEF with BHX. The co-administration of CEF and BHX has no adverse drug interaction. The increase of Vd/F may be a favorable drug interaction, which may be the mechanism of the synergistic effect of the 2 drugs. (+info)Anatomical suitability for endovascular AAA repair may affect outcomes following rupture. (7/19)
(+info)Tuberculosis should not be ignored in patients with peripheral gangrene. (8/19)
(+info)Bromhexine is a medication that is used to treat respiratory tract infections, such as bronchitis and sinusitis. It works by reducing the production of mucus in the airways, making it easier to cough up and clear. Bromhexine is available in oral solution, tablets, and syrup forms. It is usually taken two to three times a day, as directed by a healthcare provider. Common side effects of bromhexine include nausea, vomiting, and diarrhea. It is important to follow the dosage instructions provided by a healthcare provider and to inform them of any other medications you are taking before starting bromhexine.
In the medical field, "Drugs, Chinese Herbal" refers to a category of medications that are derived from plants, animals, and minerals found in China and other parts of East Asia. These medications are used to treat a wide range of conditions, including digestive disorders, respiratory problems, and pain. Chinese herbal medicine has a long history dating back thousands of years and is based on the principles of traditional Chinese medicine. It involves the use of various herbs, roots, and other natural substances that are combined to create a formula that is tailored to the individual patient's needs. Chinese herbal medicine is often used in conjunction with other forms of treatment, such as acupuncture and massage, to provide a holistic approach to healthcare. However, it is important to note that the use of Chinese herbal medicine can have potential side effects and interactions with other medications, so it is important to consult with a qualified healthcare provider before using these medications.
Bromhexine
Mollipect
Cold medicine
Ambroxol
Benadryl
Justicia adhatoda
TMPRSS2
Vasicine
Mucoactive agent
List of MeSH codes (D02)
ATC code R05
Boehringer Ingelheim
List of drugs: Br
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study
Wholesale Bromhexine,Bromhexine Manufacturer & Supplier from Pudukkottai India
Bromhexine HCL BP/EP Manufacturer,Supplier and Exporter from India
N-acetilcisteína (NAC): MedlinePlus suplementos
hydrochloride (C13H18Br2N2O) can be an dynamic N-desmethyl metabolite of bromhexine hydrochloride. - bioerc-iend.org
Ophthalmologic Manifestations of Sjogren Syndrome: Overview, Etiology and Pathophysiology, Clinical Evaluation
Influenza A(H1N1)pdm09 Virus Infection in a Captive Giant Panda, Hong Kong - Volume 25, Number 12-December 2019 - Emerging...
Dermol cream and oitnment | Adelco SA | CPHI Online
Egmedi Healthcare App - Get 15% off on medicines
Dalacin С (Clindamycin) 300 mg * 16 PFIZER - BG pharmaceuticals
Himalaya Pilex Ointment - 30g Malaysia | JH Pharmex
Anthrax Vaccine -- posts by Meryl Nass, M.D.: November 2020
Somavent Tablet - Uses, Side Effects & Composition | Consult a Doctor Online via Chat or Call
Products Archive
English (UK)
Introduction To Community Pharmacy - TPP Academy
Guaifenesin | Prescription Discount Pricing - OptionRx
藥的適應症
QualityDefects
Pesquisa | Portal Regional da BVS
Metronidazole Oral suspension BP 125mg/5ml Manufacturer, Supplier, Exporter
Not of Standard Quality Sample 2012 to 2018 | Department of Drugs Control
感冒與流感 - 「感」你知幾多? 醫護行社區藥房 - Health In Action Community
VITABIOTICS koodiga NV20 20% tavahindadelt tooted e-apteegis - Euroapteek.ee
Amlodipine and Atenolol Tablets Exporter,Amlodipine and Atenolol Tablets Exporter from Maharashtra,India
Buy Sancoril Oral Liquid (100) Online at Flat 15% OFF | PharmEasy
Duro Tuss Chesty Cough Forte 200ml, Coughs & Colds | My Pharmacy
VeriQure® - Med4Pets
Zeet Expectorant - Uses, Side Effects & Composition | Consult a Doctor Online via Chat or Call
acupuncture Archives - Health, Truth, Immune System and Coronavirus
Hydrochloride1
- hydrochloride (C13H18Br2N2O) can be an dynamic N-desmethyl metabolite of bromhexine hydrochloride. (bioerc-iend.org)
Guaifenesin1
- The salts Bromhexine, Guaifenesin are involved in the preparation of Megatuss P Syrup. (medibuddy.in)
Salts1
- The salts Bromhexine, Etophylline, Terbutaline Sulphate are involved in the preparation of Somavent Tablet. (medibuddy.in)
Mucolytic1
- injectable generation plus the mucolytic action of bromhexine that acts in the control of respiratory symptoms. (abbeyveterinarysupply.com)
Cough1
- Bromhexine HCL BP/EP is used in the treatment of respiratory problems characterized by cough & hard phlegm. (orexpharma.in)
Treatment1
- We initiated treatment with ciprofloxacin, carprofen, bromhexine, and β-glucan and fogged his living quarters twice daily with F10 antiseptic solution (1:250 dilution) containing benzalkonium chloride and polyhexanide. (cdc.gov)
Hydrochloride1
- Ambroxol hydrochloride (AMB) and bromhexine hydrochloride (BRO) are classic expectorants and bronchosecretolytic pharmaceuticals. (bvsalud.org)
Ambroxol5
- The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has started a safety review of medicines that contain ambroxol and bromhexine. (medscape.com)
- Bromhexine is largely converted into ambroxol by the body, and some reports have associated bromhexine with allergic reactions. (medscape.com)
- Question 1: How are ambroxol and bromhexine being used? (medscape.com)
- PRAC Starts Review on Ambroxol, Bromhexine Meds - Medscape - Apr 11, 2014. (medscape.com)
- Ambroxol is a metabolite of Bromhexine. (medeasy.health)
Metabolite1
- It is a metabolite of Bromhexine (Schaefer 2007 p72) . (e-lactancia.org)
Mucus1
- The popular bromhexine drops enriched with essential oils, without alcohol, sugar and dyes, liquefy and dissolve mucus in respiratory diseases and facilitate its expectoration. (senimed.cz)
Menthol1
- O munadoko pupọ bi mucolytic expectorant ti o mu yomijade ti iṣan pọ si ati dinku ni iki nitori apapọ agbara ti (Menthol ati Bromhexine).O tun jẹ itọkasi lati tọju awọn aami aisan ti o waye lati awọn akoran atẹgun gẹgẹbi iṣoro ni mimi ati sini ninu Adie.O ṣe iranlọwọ pupọ lati dinku ipa ti aapọn ajesara lẹhin aapọn Aapọn-Ikọaláìdúró, ipa sinusitis ikọ-fèé ati aapọn ooru. (joycomevet.com)
Cough1
- No, Ascoril+ cough syrup contains terbutaline, bromhexine and Guaifenesin. (pulseplus.in)
Medicines1
- Natural Medicines Comprehensive Database (La Base Exhaustiva de Datos de Medicamentos Naturales) clasifica la eficacia, basada en evidencia científica, de acuerdo a la siguiente escala: Eficaz, Probablemente Eficaz, Posiblemente Eficaz, Posiblemente Ineficaz, Probablemente Ineficaz, Ineficaz, e Insuficiente Evidencia para Hacer una Determinación. (medlineplus.gov)
Treatment1
- We initiated treatment with ciprofloxacin, carprofen, bromhexine, and β-glucan and fogged his living quarters twice daily with F10 antiseptic solution (1:250 dilution) containing benzalkonium chloride and polyhexanide. (cdc.gov)
Years1
- After two years, in 1980, the company had launched formulations of Bromhexine for the first time in India. (angelone.in)